Back

Efficacy of PCSK9 inhibitors in patients with peripheral artery disease: insights from the AT-TARGET-IT Registry

30 August 2026 (10:15 - 10:45)
Organised by: Logo
Congress Presentation Part of: New advancements in targeting atherogenic lipoproteins Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Mariafrancesca Di Santo

University of Naples Federico II, Naples (Italy)

4 More presentations in this session

Presentation thumbnail
Long-term outcomes of beta-blockers in post-MI patients with mildly reduced or preserved left ventricular ejection fraction: a systematic review and meta-analysis
Doctor K. Hosseini (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Inclisiran in combination with statin therapy achieves profound LDL-C and lipoprotein(a) reduction without acute cardiovascular events in high-risk patients with familial hypercholesterolemia
Doctor K. Dyankov (Sofia, BG)
Abstract Slides
Presentation thumbnail
Preclinical study and evaluation of S016, a novel oral small-molecule PCSK9 inhibitor
Doctor G. Cen (Chengdu - Sichuan, CN)
Abstract Slides
Presentation thumbnail
Apolipoprotein C-III inhibition reduces acute pancreatitis in familial chylomicronemia syndrome: a meta-analysis of randomized trials
Doctor K. Mahajan (Mandi, IN)

Access the full session

Session thumbnail
New advancements in targeting atherogenic lipoproteins

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study
26 August 2022
thumbnail
Congress Session
Meet the Experts: peripheral artery disease from diagnosis to interventions
25 August 2023
thumbnail
Congress Presentation
The impact of statin treatment intensity after endovascular revascularization for lower extremity peripheral artery disease
27 August 2022
thumbnail
Congress Presentation
Managing dyslipidemia in the elderly: efficacy and safety of bempedoic acid in very high-risk patients
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources